{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T10:21:25Z","timestamp":1793701285684,"version":"4.5.1"},"reference-count":47,"publisher":"American Society of Hematology","issue":"5","license":[{"start":{"date-parts":[[2024,10,22]],"date-time":"2024-10-22T00:00:00Z","timestamp":1729555200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,1,30]]},"abstract":"<jats:sec>\n                    <jats:title>Abstract<\/jats:title>\n                    <jats:p>TP53-mutant mantle cell lymphoma (MCL) is associated with poor survival outcomes with standard chemoimmunotherapy. We conducted a multicenter, phase 2 study of zanubrutinib, obinutuzumab, and venetoclax (BOVen) in untreated patients with MCL with a TP53 mutation. Patients initially received 160 mg zanubrutinib twice daily and obinutuzumab. Obinutuzumab at a dose of 1000 mg was given on cycle 1 day 1, 8, and 15, and on day 1 of cycles 2 to 8. After 2 cycles, venetoclax was added with weekly dose ramp-up to 400 mg daily. After 24 cycles, if patients were in complete remission with undetectable minimal residual disease (uMRD) using an immunosequencing assay, treatment was discontinued. The primary end point was met if \u226511 patients were progression free at 2 years. The study included 25 patients with untreated MCL with a TP53 mutation. The best overall response rate was 96% (24\/25) and the complete response rate was 88% (22\/25). Frequency of uMRD at a sensitivity level of 1\u00a0\u00d7 10\u20135 and uMRD at a sensitivity level of 1\u00a0\u00d7 10\u20136 at cycle 13 was 95% (18\/19) and 84% (16\/19), respectively. With a median follow-up of 28.2 months, the 2-year progression-free, disease-specific, and overall survival were 72%, 91%, and 76%, respectively. Common side effects were generally low grade and included diarrhea (64%), neutropenia (32%), and infusion-related reactions (24%). BOVen was well tolerated and met its primary efficacy end point in TP53-mutant MCL. These data support its use and ongoing evaluation. This trial was registered at www.ClinicalTrials.gov as #NCT03824483.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1182\/blood.2024025563","type":"journal-article","created":{"date-parts":[[2024,10,22]],"date-time":"2024-10-22T18:03:09Z","timestamp":1729620189000},"page":"497-507","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":62,"title":["Zanubrutinib, obinutuzumab, and venetoclax for first-line treatment of mantle cell lymphoma with a\u00a0\n                    <i>TP53<\/i>\n                    mutation"],"prefix":"10.1182","volume":"145","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1381-5810","authenticated-orcid":false,"given":"Anita","family":"Kumar","sequence":"first","affiliation":[{"name":"1Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacob","family":"Soumerai","sequence":"additional","affiliation":[{"name":"2Center for Lymphoma, Massachusetts General Hospital Cancer Center, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8467-9257","authenticated-orcid":false,"given":"Jeremy S.","family":"Abramson","sequence":"additional","affiliation":[{"name":"2Center for Lymphoma, Massachusetts General Hospital Cancer Center, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4867-1909","authenticated-orcid":false,"given":"Jeffrey A.","family":"Barnes","sequence":"additional","affiliation":[{"name":"2Center for Lymphoma, Massachusetts General Hospital Cancer Center, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip","family":"Caron","sequence":"additional","affiliation":[{"name":"1Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1123-5783","authenticated-orcid":false,"given":"Shalini","family":"Chhabra","sequence":"additional","affiliation":[{"name":"3Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Chabowska","sequence":"additional","affiliation":[{"name":"1Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6576-5256","authenticated-orcid":false,"given":"Ahmet","family":"Dogan","sequence":"additional","affiliation":[{"name":"4Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorenzo","family":"Falchi","sequence":"additional","affiliation":[{"name":"1Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2931-886X","authenticated-orcid":false,"given":"Clare","family":"Grieve","sequence":"additional","affiliation":[{"name":"1Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. Erika","family":"Haydu","sequence":"additional","affiliation":[{"name":"2Center for Lymphoma, Massachusetts General Hospital Cancer Center, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3943-6608","authenticated-orcid":false,"given":"Patrick Connor","family":"Johnson","sequence":"additional","affiliation":[{"name":"2Center for Lymphoma, Massachusetts General Hospital Cancer Center, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1699-5666","authenticated-orcid":false,"given":"Ashlee","family":"Joseph","sequence":"additional","affiliation":[{"name":"1Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hailey E.","family":"Kelly","sequence":"additional","affiliation":[{"name":"2Center for Lymphoma, Massachusetts General Hospital Cancer Center, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alyssa","family":"Labarre","sequence":"additional","affiliation":[{"name":"1Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer Kimberly","family":"Lue","sequence":"additional","affiliation":[{"name":"1Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosalba","family":"Martignetti","sequence":"additional","affiliation":[{"name":"2Center for Lymphoma, Massachusetts General Hospital Cancer Center, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joanna","family":"Mi","sequence":"additional","affiliation":[{"name":"1Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alison","family":"Moskowitz","sequence":"additional","affiliation":[{"name":"1Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Colette","family":"Owens","sequence":"additional","affiliation":[{"name":"1Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sean","family":"Plummer","sequence":"additional","affiliation":[{"name":"2Center for Lymphoma, Massachusetts General Hospital Cancer Center, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Madeline","family":"Puccio","sequence":"additional","affiliation":[{"name":"2Center for Lymphoma, Massachusetts General Hospital Cancer Center, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9541-8666","authenticated-orcid":false,"given":"Gilles","family":"Salles","sequence":"additional","affiliation":[{"name":"1Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9258-2698","authenticated-orcid":false,"given":"Venkatraman","family":"Seshan","sequence":"additional","affiliation":[{"name":"5Department of Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth","family":"Simkins","sequence":"additional","affiliation":[{"name":"2Center for Lymphoma, Massachusetts General Hospital Cancer Center, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalie","family":"Slupe","sequence":"additional","affiliation":[{"name":"1Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Honglei","family":"Zhang","sequence":"additional","affiliation":[{"name":"3Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1403-6883","authenticated-orcid":false,"given":"Andrew D.","family":"Zelenetz","sequence":"additional","affiliation":[{"name":"1Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"20","key":"2025013016203605500_bib1","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1182\/blood-2016-01-643569","article-title":"The 2016 revision of the World Health Organization classification of lymphoid neoplasms","volume":"127","author":"Swerdlow","year":"2016","journal-title":"Blood"},{"issue":"10","key":"2025013016203605500_bib2","doi-asserted-by":"crossref","first-page":"3416","DOI":"10.1172\/JCI61272","article-title":"Molecular pathogenesis of mantle cell lymphoma","volume":"122","author":"Jares","year":"2012","journal-title":"J\u00a0Clin Invest"},{"issue":"3","key":"2025013016203605500_bib3","doi-asserted-by":"crossref","first-page":"e153283","DOI":"10.1172\/JCI153283","article-title":"Genomic and transcriptomic profiling reveals distinct molecular subsets associated with outcomes in mantle cell lymphoma","volume":"132","author":"Yi","year":"2022","journal-title":"J\u00a0Clin Invest"},{"issue":"45","key":"2025013016203605500_bib4","doi-asserted-by":"crossref","first-page":"18250","DOI":"10.1073\/pnas.1314608110","article-title":"Landscape of somatic mutations and clonal evolution in mantle cell lymphoma","volume":"110","author":"Be\u00e0","year":"2013","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"12","key":"2025013016203605500_bib5","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1182\/blood.2020005289","article-title":"Genomic and epigenomic insights into the origin, pathogenesis, and clinical behavior of mantle cell lymphoma subtypes","volume":"136","author":"Nadeu","year":"2020","journal-title":"Blood"},{"issue":"4","key":"2025013016203605500_bib6","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1182\/blood-2017-07-797019","article-title":"Expression of TP53 is associated with the outcome of MCL independent of MIPI and Ki-67 in trials of the European MCL Network","volume":"131","author":"Aukema","year":"2018","journal-title":"Blood"},{"issue":"17","key":"2025013016203605500_bib7","doi-asserted-by":"crossref","first-page":"1903","DOI":"10.1182\/blood-2017-04-779736","article-title":"TP53 mutations identify younger mantle cell lymphoma patients who do not benefit from intensive chemoimmunotherapy","volume":"130","author":"Eskelund","year":"2017","journal-title":"Blood"},{"issue":"6","key":"2025013016203605500_bib8","doi-asserted-by":"crossref","first-page":"1604","DOI":"10.3324\/haematol.2018.214056","article-title":"KMT2D mutations and TP53 disruptions are poor prognostic biomarkers in mantle cell lymphoma receiving high-dose therapy: a FIL study","volume":"105","author":"Ferrero","year":"2020","journal-title":"Haematologica"},{"issue":"11","key":"2025013016203605500_bib9","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.6004\/jnccn.2023.0057","article-title":"NCCN guidelines\u00ae insights: B-cell lymphomas, version 6.2023","volume":"21","author":"Zelenetz","year":"2023","journal-title":"J\u00a0Natl Compr Canc Netw"},{"issue":"6","key":"2025013016203605500_bib10","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1056\/NEJMoa1306220","article-title":"Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma","volume":"369","author":"Wang","year":"2013","journal-title":"N\u00a0Engl J Med"},{"issue":"10121","key":"2025013016203605500_bib11","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1016\/S0140-6736(17)33108-2","article-title":"Acalabrutinib in relapsed or refractory mantle cell lymphoma (ACE-LY-004): a single-arm, multicentre, phase 2 trial","volume":"391","author":"Wang","year":"2018","journal-title":"Lancet"},{"issue":"12","key":"2025013016203605500_bib12","doi-asserted-by":"crossref","first-page":"2577","DOI":"10.1182\/bloodadvances.2020004074","article-title":"Zanubrutinib for the treatment of relapsed or refractory mantle cell lymphoma","volume":"5","author":"Tam","year":"2021","journal-title":"Blood Adv"},{"issue":"13","key":"2025013016203605500_bib13","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1056\/NEJMoa1715519","article-title":"Ibrutinib plus venetoclax for the treatment of mantle-cell lymphoma","volume":"378","author":"Tam","year":"2018","journal-title":"N\u00a0Engl J Med"},{"issue":"7","key":"2025013016203605500_bib14","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1182\/blood.2020008727","article-title":"Ibrutinib, obinutuzumab, and venetoclax in relapsed and untreated patients with mantle cell lymphoma: a phase 1\/2 trial","volume":"137","author":"Le Gouill","year":"2021","journal-title":"Blood"},{"issue":"29","key":"2025013016203605500_bib15","doi-asserted-by":"crossref","first-page":"13075","DOI":"10.1073\/pnas.1004594107","article-title":"The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy","volume":"107","author":"Honigberg","year":"2010","journal-title":"Proc Natl Acad Sci U\u00a0S\u00a0A"},{"issue":"2","key":"2025013016203605500_bib16","doi-asserted-by":"crossref","first-page":"e76","DOI":"10.3324\/haematol.2019.220590","article-title":"Differential effects of BTK inhibitors ibrutinib and zanubrutinib on NK-cell effector function in patients with mantle cell lymphoma","volume":"105","author":"Flinsenberg","year":"2020","journal-title":"Haematologica"},{"issue":"17","key":"2025013016203605500_bib17","doi-asserted-by":"crossref","first-page":"7923","DOI":"10.1021\/acs.jmedchem.9b00687","article-title":"Discovery of zanubrutinib (BGB-3111), a novel, potent, and selective covalent inhibitor of Bruton\u2019s tyrosine kinase","volume":"62","author":"Guo","year":"2019","journal-title":"J\u00a0Med Chem"},{"issue":"11","key":"2025013016203605500_bib18","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1182\/blood.2019001160","article-title":"Phase 1 study of the selective BTK inhibitor zanubrutinib in B-cell malignancies and safety and efficacy evaluation in CLL","volume":"134","author":"Tam","year":"2019","journal-title":"Blood"},{"issue":"18","key":"2025013016203605500_bib19","doi-asserted-by":"crossref","first-page":"2038","DOI":"10.1182\/blood.2020006844","article-title":"A\u00a0randomized phase 3 trial of zanubrutinib vs ibrutinib in symptomatic Waldenstr\u00f6m macroglobulinemia: the ASPEN study","volume":"136","author":"Tam","year":"2020","journal-title":"Blood"},{"issue":"4","key":"2025013016203605500_bib20","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1056\/NEJMoa2211582","article-title":"Zanubrutinib or ibrutinib in relapsed or refractory chronic lymphocytic leukemia","volume":"388","author":"Brown","year":"2023","journal-title":"N\u00a0Engl J Med"},{"issue":"21","key":"2025013016203605500_bib21","doi-asserted-by":"crossref","first-page":"3148","DOI":"10.1182\/blood.2021014162","article-title":"Zanubrutinib in relapsed\/refractory mantle cell lymphoma: long-term efficacy and safety results from a phase 2 study","volume":"139","author":"Song","year":"2022","journal-title":"Blood"},{"issue":"5","key":"2025013016203605500_bib22","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1016\/j.hoc.2020.06.006","article-title":"Minimal residual disease in mantle cell lymphoma: methods and clinical significance","volume":"34","author":"Ladetto","year":"2020","journal-title":"Hematol Oncol Clin North Am"},{"issue":"11","key":"2025013016203605500_bib23","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1200\/JCO.21.02321","article-title":"Ibrutinib in combination with rituximab for indolent clinical forms of mantle cell lymphoma (IMCL-2015): a multicenter, open-label, single-arm, phase II trial","volume":"40","author":"Gin\u00e9","year":"2022","journal-title":"J\u00a0Clin Oncol"},{"issue":"27","key":"2025013016203605500_bib24","doi-asserted-by":"crossref","first-page":"3059","DOI":"10.1200\/JCO.2013.54.8800","article-title":"Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification","volume":"32","author":"Cheson","year":"2014","journal-title":"J\u00a0Clin Oncol"},{"issue":"1","key":"2025013016203605500_bib25","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1186\/s12885-020-07077-9","article-title":"Analytical evaluation of the clonoSEQ Assay for establishing measurable (minimal) residual disease in acute lymphoblastic leukemia, chronic lymphocytic leukemia, and multiple myeloma","volume":"20","author":"Ching","year":"2020","journal-title":"BMC Cancer"},{"key":"2025013016203605500_bib26","unstructured":"R: R Core Team\n          . A language and environment for statistical computing [internet]. Accessed 1 June 2024. https:\/\/www.R-project.org\/."},{"issue":"1","key":"2025013016203605500_bib27","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1038\/s41591-018-0243-z","article-title":"Dynamic molecular monitoring reveals that SWI-SNF mutations mediate resistance to ibrutinib plus venetoclax in mantle cell lymphoma","volume":"25","author":"Agarwal","year":"2019","journal-title":"Nat Med"},{"issue":"18","key":"2025013016203605500_bib28","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1182\/blood.2023020211","article-title":"CARD11 gain of function upregulates BCL2A1 expression and promotes resistance to targeted therapies combination in B-cell lymphoma","volume":"142","author":"Decombis","year":"2023","journal-title":"Blood"},{"issue":"19","key":"2025013016203605500_bib29","doi-asserted-by":"crossref","first-page":"1844","DOI":"10.1056\/NEJMra0904569","article-title":"The tumor lysis syndrome","volume":"364","author":"Howard","year":"2011","journal-title":"N\u00a0Engl J Med"},{"issue":"26","key":"2025013016203605500_bib30","doi-asserted-by":"crossref","first-page":"2482","DOI":"10.1056\/NEJMoa2201817","article-title":"Ibrutinib plus bendamustine and rituximab in untreated mantle-cell lymphoma","volume":"386","author":"Wang","year":"2022","journal-title":"N\u00a0Engl J Med"},{"issue":"10441","key":"2025013016203605500_bib31","doi-asserted-by":"crossref","first-page":"2293","DOI":"10.1016\/S0140-6736(24)00184-3","article-title":"Ibrutinib combined with immunochemotherapy with or without autologous stem-cell transplantation versus immunochemotherapy and autologous stem-cell transplantation in previously untreated patients with mantle cell lymphoma (TRIANGLE): a three-arm, randomised, open-label, phase 3 superiority trial of the European Mantle Cell Lymphoma Network","volume":"403","author":"Dreyling","year":"2024","journal-title":"The Lancet"},{"issue":"10","key":"2025013016203605500_bib32","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1016\/S1470-2045(16)30212-1","article-title":"Ibrutinib for patients with relapsed or refractory chronic lymphocytic leukaemia with 17p deletion (RESONATE-17): a phase 2, open-label, multicentre study","volume":"17","author":"O\u2019Brien","year":"2016","journal-title":"Lancet Oncol"},{"issue":"6","key":"2025013016203605500_bib33","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1016\/S1470-2045(16)30019-5","article-title":"Venetoclax in relapsed or refractory chronic lymphocytic leukaemia with 17p deletion: a multicentre, open-label, phase 2 study","volume":"17","author":"Stilgenbauer","year":"2016","journal-title":"Lancet Oncol"},{"issue":"19","key":"2025013016203605500_bib34","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1056\/NEJMoa1505237","article-title":"Lenalidomide plus rituximab as initial treatment for mantle-cell lymphoma","volume":"373","author":"Ruan","year":"2015","journal-title":"N\u00a0Engl J Med"},{"issue":"2","key":"2025013016203605500_bib35","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1200\/JCO.21.01797","article-title":"Ibrutinib with rituximab in first-line treatment of older patients with mantle cell lymphoma","volume":"40","author":"Jain","year":"2022","journal-title":"J\u00a0Clin Oncol"},{"issue":"16","key":"2025013016203605500_bib36","doi-asserted-by":"crossref","first-page":"4518","DOI":"10.1182\/bloodadvances.2023009992","article-title":"Adding venetoclax to lenalidomide and rituximab is safe and effective in patients with untreated mantle cell lymphoma","volume":"7","author":"Phillips","year":"2023","journal-title":"Blood Adv"},{"issue":"17","key":"2025013016203605500_bib37","doi-asserted-by":"crossref","first-page":"4539","DOI":"10.1182\/bloodadvances.2023012424","article-title":"Acalabrutinib plus venetoclax and rituximab in treatment-naive mantle cell lymphoma: 2-year safety and efficacy analysis","volume":"8","author":"Wang","year":"2024","journal-title":"Blood Adva"},{"issue":"12","key":"2025013016203605500_bib38","doi-asserted-by":"crossref","first-page":"e879","DOI":"10.1016\/S2352-3026(21)00307-0","article-title":"Zanubrutinib, obinutuzumab, and venetoclax with minimal residual disease-driven discontinuation in previously untreated patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: a multicentre, single-arm, phase 2 trial","volume":"8","author":"Soumerai","year":"2021","journal-title":"Lancet Haematol"},{"issue":"24","key":"2025013016203605500_bib39","doi-asserted-by":"crossref","first-page":"2808","DOI":"10.1182\/blood-2016-06-720490","article-title":"Rational targeted therapies to overcome microenvironment-dependent expansion of mantle cell lymphoma","volume":"128","author":"Chiron","year":"2016","journal-title":"Blood"},{"issue":"suppl 1","key":"2025013016203605500_bib40","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1182\/blood-2023-174416","article-title":"Obinutuzumab versus rituximab in transplant eligible untreated MCL patients, a matching comparison between the Lyma and Lyma-101 trials","volume":"142","author":"Sarkozy","year":"2023","journal-title":"Blood"},{"issue":"1","key":"2025013016203605500_bib41","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1111\/bjh.12854","article-title":"SOX11 and TP53 add prognostic information to MIPI in a homogenously treated cohort of mantle cell lymphoma--a Nordic Lymphoma Group study","volume":"166","author":"Nordstr\u00f6m","year":"2014","journal-title":"Br J Haematol"},{"issue":"14","key":"2025013016203605500_bib42","doi-asserted-by":"crossref","first-page":"3504","DOI":"10.1080\/10428194.2022.2118529","article-title":"p53 immunohistochemistry must be confirmed by TP53 next generation sequencing for accurate risk stratification of patients with mantle cell lymphoma","volume":"63","author":"Nolan","year":"2022","journal-title":"Leuk Lymphoma"},{"issue":"4","key":"2025013016203605500_bib43","first-page":"1171","article-title":"MYC protein is a high-risk factor in mantle cell lymphoma and identifies cases beyond morphology, proliferation and TP53\/p53 - a Nordic Lymphoma Group study","volume":"109","author":"Rodrigues","year":"2024","journal-title":"Haematologica"},{"issue":"10","key":"2025013016203605500_bib44","doi-asserted-by":"crossref","first-page":"4302","DOI":"10.1182\/blood.V87.10.4302.bloodjournal87104302","article-title":"p53 mutations in mantle cell lymphoma are associated with variant cytology and predict a poor prognosis","volume":"87","author":"Greiner","year":"1996","journal-title":"Blood"},{"issue":"4","key":"2025013016203605500_bib45","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1182\/blood-2018-03-838136","article-title":"A\u00a0gene signature that distinguishes conventional and leukemic nonnodal mantle cell lymphoma helps predict outcome","volume":"132","author":"Clot","year":"2018","journal-title":"Blood"},{"issue":"8","key":"2025013016203605500_bib46","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1007\/s11864-023-01102-2","article-title":"Utility of measurable residual disease (MRD) assessment in mantle cell lymphoma","volume":"24","author":"Wu","year":"2023","journal-title":"Curr Treat Options Oncol"},{"issue":"3","key":"2025013016203605500_bib47","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1200\/JCO.22.01661","article-title":"Frontline therapy in mantle cell lymphoma: when clinical trial and real-world data collide","volume":"41","author":"Fenske","year":"2023","journal-title":"J\u00a0Clin Oncol"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/145\/5\/497\/2353506\/blood_bld-2024-025563-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/145\/5\/497\/2353506\/blood_bld-2024-025563-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,30]],"date-time":"2025-01-30T11:20:56Z","timestamp":1738236056000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/145\/5\/497\/518286\/Zanubrutinib-obinutuzumab-and-venetoclax-for-first"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,30]]},"references-count":47,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,1,30]]}},"URL":"https:\/\/doi.org\/10.1182\/blood.2024025563","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,30]]}}}